457 related articles for article (PubMed ID: 22830335)
21. Small-molecule inhibitors of MDM2 as new anticancer therapeutics.
Dickens MP; Fitzgerald R; Fischer PM
Semin Cancer Biol; 2010 Feb; 20(1):10-8. PubMed ID: 19897042
[TBL] [Abstract][Full Text] [Related]
22. Resistance mechanisms to inhibitors of p53-MDM2 interactions in cancer therapy: can we overcome them?
Haronikova L; Bonczek O; Zatloukalova P; Kokas-Zavadil F; Kucerikova M; Coates PJ; Fahraeus R; Vojtesek B
Cell Mol Biol Lett; 2021 Dec; 26(1):53. PubMed ID: 34911439
[TBL] [Abstract][Full Text] [Related]
23. Patented inhibitors of p53-Mdm2 interaction (2006 - 2008).
Weber L
Expert Opin Ther Pat; 2010 Feb; 20(2):179-91. PubMed ID: 20100001
[TBL] [Abstract][Full Text] [Related]
24. Molecular pathways: targeting Mdm2 and Mdm4 in cancer therapy.
Li Q; Lozano G
Clin Cancer Res; 2013 Jan; 19(1):34-41. PubMed ID: 23262034
[TBL] [Abstract][Full Text] [Related]
25. 1,4,5-Trisubstituted Imidazole-Based p53-MDM2/MDMX Antagonists with Aliphatic Linkers for Conjugation with Biological Carriers.
Twarda-Clapa A; Krzanik S; Kubica K; Guzik K; Labuzek B; Neochoritis CG; Khoury K; Kowalska K; Czub M; Dubin G; Dömling A; Skalniak L; Holak TA
J Med Chem; 2017 May; 60(10):4234-4244. PubMed ID: 28482147
[TBL] [Abstract][Full Text] [Related]
26. Discovery of SCY45, a Natural Small-Molecule MDM2-p53 Interaction Inhibitor.
Gong H; An J; Dong Q; Li J; Yang W; Sun W; Su Z; Zhang S
Chem Biodivers; 2019 Jun; 16(6):e1900081. PubMed ID: 30989812
[TBL] [Abstract][Full Text] [Related]
27. Small-molecule inhibitors of the p53-MDM2 interaction.
Vu BT; Vassilev L
Curr Top Microbiol Immunol; 2011; 348():151-72. PubMed ID: 21046355
[TBL] [Abstract][Full Text] [Related]
28. MDM2 and MDM4: p53 regulators as targets in anticancer therapy.
Toledo F; Wahl GM
Int J Biochem Cell Biol; 2007; 39(7-8):1476-82. PubMed ID: 17499002
[TBL] [Abstract][Full Text] [Related]
29. MDM2/X inhibitors under clinical evaluation: perspectives for the management of hematological malignancies and pediatric cancer.
Tisato V; Voltan R; Gonelli A; Secchiero P; Zauli G
J Hematol Oncol; 2017 Jul; 10(1):133. PubMed ID: 28673313
[TBL] [Abstract][Full Text] [Related]
30. Recent Advancements in the Discovery of MDM2/MDM2-p53 Interaction Inhibitors for the Treatment of Cancer.
Bhatia N; Khator R; Kulkarni S; Singh Y; Kumar P; Thareja S
Curr Med Chem; 2023; 30(32):3668-3701. PubMed ID: 37190755
[TBL] [Abstract][Full Text] [Related]
31. Discovery, synthesis, and biological evaluation of orally active pyrrolidone derivatives as novel inhibitors of p53-MDM2 protein-protein interaction.
Zhuang C; Miao Z; Zhu L; Dong G; Guo Z; Wang S; Zhang Y; Wu Y; Yao J; Sheng C; Zhang W
J Med Chem; 2012 Nov; 55(22):9630-42. PubMed ID: 23046248
[TBL] [Abstract][Full Text] [Related]
32. Small molecule antagonists of the MDM2 oncoprotein as anticancer agents.
Buolamwini JK; Addo J; Kamath S; Patil S; Mason D; Ores M
Curr Cancer Drug Targets; 2005 Feb; 5(1):57-68. PubMed ID: 15720190
[TBL] [Abstract][Full Text] [Related]
33. Two Birds with One Stone: NFAT1-MDM2 Dual Inhibitors for Cancer Therapy.
Wang W; Zafar A; Rajaei M; Zhang R
Cells; 2020 May; 9(5):. PubMed ID: 32397368
[TBL] [Abstract][Full Text] [Related]
34. p53-Mdm2 Interaction Inhibitors as Novel Nongenotoxic Anticancer Agents.
Nayak SK; Khatik GL; Narang R; Monga V; Chopra HK
Curr Cancer Drug Targets; 2018; 18(8):749-772. PubMed ID: 28669344
[TBL] [Abstract][Full Text] [Related]
35. MDM2 small-molecule antagonist RG7112 activates p53 signaling and regresses human tumors in preclinical cancer models.
Tovar C; Graves B; Packman K; Filipovic Z; Higgins B; Xia M; Tardell C; Garrido R; Lee E; Kolinsky K; To KH; Linn M; Podlaski F; Wovkulich P; Vu B; Vassilev LT
Cancer Res; 2013 Apr; 73(8):2587-97. PubMed ID: 23400593
[TBL] [Abstract][Full Text] [Related]
36. Synthesis and biological evaluation of thio-benzodiazepines as novel small molecule inhibitors of the p53-MDM2 protein-protein interaction.
Zhuang C; Miao Z; Zhu L; Zhang Y; Guo Z; Yao J; Dong G; Wang S; Liu Y; Chen H; Sheng C; Zhang W
Eur J Med Chem; 2011 Nov; 46(11):5654-61. PubMed ID: 21996465
[TBL] [Abstract][Full Text] [Related]
37. An overview of PROTACs targeting MDM2 as a novel approach for cancer therapy.
Li H; Cai X; Yang X; Zhang X
Eur J Med Chem; 2024 Jun; 272():116506. PubMed ID: 38761584
[TBL] [Abstract][Full Text] [Related]
38. Small molecule inhibitors of the p53-MDM2.
Hu CQ; Hu YZ
Curr Med Chem; 2008; 15(17):1720-30. PubMed ID: 18673221
[TBL] [Abstract][Full Text] [Related]
39. MDM2-p53 Interaction Inhibitors: The Current State-of-Art and Updated Patent Review (2010-Present).
Rusiecki R; Witkowski J; Jaszczewska-Adamczak J
Recent Pat Anticancer Drug Discov; 2019; 14(4):324-369. PubMed ID: 31642413
[TBL] [Abstract][Full Text] [Related]
40. Medicinal Chemistry Strategies to Disrupt the p53-MDM2/MDMX Interaction.
Lemos A; Leão M; Soares J; Palmeira A; Pinto M; Saraiva L; Sousa ME
Med Res Rev; 2016 Sep; 36(5):789-844. PubMed ID: 27302609
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
